Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
Journal of Clinical Anesthesia|February 18, 2024
Thoracic impedance pneumography in propofol-sedated patients undergoing percutaneous endoscopic gastrostomy (PEG) placement in gastrointestinal endoscopy: A prospective, randomized trialF A Michael, D Hessz, C Graf, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 19, 2020
Severe underquantification of HIV-1 group O isolates by major commercial PCR-based assaysA Berger, M Muenchhoff, K Hourfar, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2005
The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuationM van Zonneveld, H J Flink, E Verhey, et al.
Journal of Viral Hepatitis|October 15, 2013
The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infectionA J van der Meer, B J Veldt, J J Feld, et al.
Journal of Viral Hepatitis|November 4, 2014
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studiesM P Manns, M W Fried, S Zeuzem, et al.
Alimentary Pharmacology & Therapeutics|March 15, 2018
High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infectionJ von Felden, J Vermehren, P Ingiliz, et al.
Journal of Viral Hepatitis|October 31, 2013
The new paradigm of hepatitis C therapy: integration of oral therapies into best practicesN H Afdhal, S Zeuzem, R T Schooley, et al.
Journal of Viral Hepatitis|March 26, 2017
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C RegistryT M Welzel, H Hinrichsen, C Sarrazin, et al.
Journal of Viral Hepatitis|August 7, 2012
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3S Pianko, S Zeuzem, W-L Chuang, et al.
Alimentary Pharmacology & Therapeutics|August 5, 2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)S Zeuzem, R Flisiak, J M Vierling, et al.
Pageof 30